Health - Google News: Equity Briefing Healthcare Review: Alnylam Pharmaceuticals & Human Genome Jump ... - Reuters

Health - Google News Google News

Equity Briefing Healthcare Review: Alnylam Pharmaceuticals & Human Genome Jump ... - Reuters Jul 16th 2012, 19:01 Proactive Investors USA & Canada Equity Briefing Healthcare Review: Alnylam Pharmaceuticals & Human Genome Jump ... Reuters Human Genome Sciences (NASDAQ:HGSI) shares climbed 4.60% to $14.20 after GlaxoSmithKline and Human Genome Sciences today announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per share in ... Alnylam Gains on Treatment Data for Deadly Nerve DiseaseBloomberg Alnylam gains on treatment data for deadly nerve, heart diseaseBoston Globe Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust Knockdown of ...EON: Enhanced Online News (press release) MarketWatch -RTT News all 56 news articles »

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

Posted in: